Xifaxan revenue trends
In 3Q17, Valeant Pharmaceuticals’ (VRX) Xifaxan reported revenues of $286 million, which was ~5% higher on a YoY (year-over-year) basis and a 23% rise quarter-over-quarter. Xifaxan reported revenues of $704 million for the first nine months of 2017.
Xifaxan is used in the treatment of travelers’ diarrhea, triggered by noninvasive strains of Escherichia coli in individuals aged above 12 years as well as irritable bowel syndrome with diarrhea. Xifaxan is also used for decreasing the risk of overt hepatic encephalopathy relapse in adults.
In the marketplace, Xifaxan’s competition includes Johnson & Johnson’s (JNJ) Imodium and Levaquin and Pfizer’s (PFE) Zithromax. The rising sales of Valeant’s branded prescription products could boost the share prices of the Guru Activist Index ETF (ACTX). Valeant makes up ~0.56% of ACTX’s total portfolio holdings.
Apriso and Uceris revenue trends
In 3Q17, Apriso generated revenues of $42 million, which was ~11% higher on a YoY basis and 8% higher quarter-over-quarter. Apriso reported revenues of $110 million for the first nine months of 2017.
In 3Q17, Uceris generated revenues of $37 million, which was ~8% higher on a YoY basis and 6% higher quarter-over-quarter.
Apriso and Uceris (budesonide) are used for the treatment of adult individuals with mild to moderate ulcerative colitis. In the marketplace, Apriso’s and Uceris’s competition includes Allergan’s (AGN) Asacol HD.
Glumetza revenue trends
In 3Q17, Glumetza reported revenues of $46 million, compared with $24 million in 3Q16, reflecting a 94% rise on a YoY basis and a 24% rise quarter-over-quarter. Glumetza reported revenues of $106 million for the first nine months of 2017.
Glumetza (metformin HCl) is used for the treatment of type-2 diabetes mellitus.